BMS-8

Research use only, not for human use.

BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.

BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.(In Vitro):BMS-8 has a more stable binding mode with one PD-L1 monomer than the other and the small-molecule inducing PD-L1 dimerization was further stabilized by the non-polar interaction of Ile54, Tyr56, Met115, Ala121, and Tyr123 on both monomers and the water bridges involved in ALys124.

BMS-8 tends to have a more stable binding mode with one PD-L1 monomer than the other and the small-molecule inducing PD-L1 dimerization was further stabilized by the non-polar interaction of Ile54, Tyr56, Met115, Ala121, and Tyr123 on both monomers and the water bridges involved in ALys124.

——

BMS8 | BMS 8 | BMS-8

Immunology/Inflammation

PD-1/PD-L1

Wnt/beta-catenin

——

——

1675201-90-7

494.429

C27H28BrNO3

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (168.54 mM)

Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years